CASTELLI, Riccardo
 Distribuzione geografica
Continente #
EU - Europa 1.372
NA - Nord America 1.289
AS - Asia 465
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.129
Nazione #
US - Stati Uniti d'America 1.282
IT - Italia 502
CN - Cina 317
IE - Irlanda 317
SE - Svezia 205
FI - Finlandia 148
DE - Germania 77
TR - Turchia 65
IN - India 45
FR - Francia 43
BE - Belgio 21
HK - Hong Kong 18
GB - Regno Unito 14
CZ - Repubblica Ceca 10
SG - Singapore 8
CA - Canada 7
AT - Austria 5
NL - Olanda 5
RO - Romania 5
UA - Ucraina 5
PL - Polonia 4
VN - Vietnam 4
IR - Iran 3
LU - Lussemburgo 3
CH - Svizzera 2
ES - Italia 2
TW - Taiwan 2
A1 - Anonimo 1
BG - Bulgaria 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
JP - Giappone 1
MC - Monaco 1
MY - Malesia 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 3.129
Città #
Dublin 313
Chandler 291
Ann Arbor 204
Parma 174
Ashburn 81
Dearborn 76
Beijing 61
Izmir 58
Shanghai 55
Princeton 52
Wilmington 44
Boardman 34
Nanjing 33
Bremen 31
New York 28
Bangalore 27
Helsinki 24
Los Angeles 21
Jinan 18
Modena 18
Brussels 16
Des Moines 16
Nanchang 16
Seattle 16
Shenyang 15
Hebei 14
Fremont 13
Brescia 12
Guangzhou 12
Hong Kong 12
Tianjin 12
Düsseldorf 11
Prata Di Pordenone 11
Woodbridge 11
Rome 10
Bologna 9
Kunming 9
Norwalk 9
San Mateo 8
Zhengzhou 8
Ankara 7
London 7
Ascoli Piceno 6
Borås 6
Fairfield 6
Follonica 6
Grafing 6
Hangzhou 6
Milan 6
Pune 6
Acqui Terme 5
Brno 5
Changsha 5
Hefei 5
Jiaxing 5
Montegaldella 5
Rocca Canavese 5
Taizhou 5
Verona 5
Ardea 4
Caorso 4
Dong Ket 4
Houston 4
Pavia 4
Pesaro 4
Phoenix 4
Quattro Castella 4
Redwood City 4
Rimini 4
Soliera 4
Vienna 4
Council Bluffs 3
Ferrara 3
Frankfurt am Main 3
Fuzhou 3
Genoa 3
Hyderabad 3
Jacksonville 3
Kraków 3
Leuven 3
Lubbock 3
Luxembourg 3
Mareo 3
Paris 3
Piacenza 3
Redmond 3
Reggio Nell'emilia 3
Trento 3
Vigevano 3
Washington 3
Aberdeen 2
Baotou 2
Bergamo 2
Braunschweig 2
Corniglio 2
Cremona 2
Duncan 2
Falls Church 2
Fidenza 2
Florence 2
Totale 2.115
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 194
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 151
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 129
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 114
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 102
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 97
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 96
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 95
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 92
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 79
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 77
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 74
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 73
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 72
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 71
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 68
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 67
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 67
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 67
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 67
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 66
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 64
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 63
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 61
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 59
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 53
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 53
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 51
2,2-dimethyl-4-(4-methoxy-phenoxy) butanoate and 2,2-dimethyl-4-azido butanoate: Two new pivaloate-ester-like protecting groups 50
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 49
Synthesis of the Lewis a trisaccharide based on an anomeric silyl fluorous tag 48
MicroPET Evaluation of a Hydroxamate-Based MMP Inhibitor, [18F]FB-ML5, in a Mouse Model of Cigarette Smoke-Induced Acute Airway Inflammation 46
Fibroblast growth factor receptor inhibitors: patent review (2015–2019) 46
Adlayers of dimannoside thiols on gold: Surface chemical analysis 44
Hierarchical Self-Assembly of Luminescent Eu(III) Complexes on Silicon 43
Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry 43
Fatty acid amide hydrolase inhibitors: a patent review (2009 - 2014) 41
2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors 39
Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin 38
Discrimination of Escherichia coli strains using glycan cantilever array sensors 37
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 36
Activation of glycosyl halides by halogen bonding 34
Synthesis of C-Glycosyl Amino Acid Building Blocks Suitable for the Solid-Phase Synthesis of Multivalent Glycopeptide Mimics 33
Critical role of amino acid position 343 of surfactant protein-D in the selective binding of glycolipids from Mycobacterium tuberculosis 32
A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [18F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging 32
Surface analytical characterization of carbohydrate microarrays 29
Cantilever array sensors detect specific carbohydrate-protein interactions with picomolar sensitivity 28
Semisynthesis of a glycosylphosphatidylinositol-anchored prion protein 25
Total synthesis of the triglycosyl phenolic glycolipid PGL-tb1 from mycobacterium tuberculosis 25
Multiple modes of binding enhance the affinity of DC-SIGN for high mannose N-linked glycans found on viral glycoproteins 23
FGF trapping inhibits multiple myeloma growth through c-Myc degradation–induced mitochondrial oxidative stress 23
Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88 21
Multimethod chemical characterization of carbohydrate-functionalized surfaces 20
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 16
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 14
Froc: A new fluorous protective group for peptide and oligosaccharide synthesis 14
Plumieribetin, a fish lectin homologous to mannose-binding B-type lectins, inhibits the collagen-binding α1β1 integrin 14
Totale 3.265
Categoria #
all - tutte 11.460
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.460


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201965 0 0 0 0 0 0 0 0 0 0 63 2
2019/2020535 71 50 9 11 25 79 72 20 47 100 33 18
2020/2021350 9 11 33 36 56 38 42 22 40 16 10 37
2021/2022344 21 15 15 35 32 12 36 29 23 16 9 101
2022/20231.209 129 134 60 71 98 139 17 70 384 22 70 15
2023/2024411 36 29 23 17 37 87 63 50 24 42 3 0
Totale 3.265